SCHEMBL10025019

SCHEMBL10025019

COc1ccc(N(c2ccc(-c3ccc(N(c4ccc(C)cc4)c4ccc(-c5ccc(N(c6ccc(OC)cc6)c6ccc7c(c6)C(C)(C)c6ccccc6-7)cc5)cc4)cc3)cc2)c2ccc(-c3ccc(N(c4ccc(C)cc4)c4ccc5c(c4)C(C)(C)c4ccccc4-5)cc3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 4/20 0.45
ABL1 P00519 1/20 0.38
ABCB1 P08183 1/20 0.38
BCR P11274 1/20 0.38
PGR P06401 1/20 0.38
ALKBH3 Q96Q83 3/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
ACHE P22303 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 2/20 0.35
RPS6KA2 Q15349 1/20 0.34
FLT3 P36888 1/20 0.34
ALDH1A1 P00352 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10025024 1.00 PDK2 (0.45) PDK2ABL1ABCB1BCRPGR
SCHEMBL10057800 0.95 PDK2 (0.49) PDK2ABL1ABCB1BCRPGR
SCHEMBL17735813 0.95 PDK2 (0.49) PDK2ABL1ABCB1BCRPGR
SCHEMBL10058152 0.95 PDK2 (0.49) PDK2ABL1ABCB1BCRPGR
SCHEMBL10025022 0.94 PGR (0.39) PDK2ABL1ABCB1BCRPGR
SCHEMBL10025016 0.94 ACHE (0.42) PDK2ALKBH3KMT2AMEN1ACHE
SCHEMBL10025029 0.94 ACHE (0.42) PDK2ALKBH3KMT2AMEN1ACHE
SCHEMBL15185753 0.91 PGR (0.44) PDK2ABL1ABCB1BCRPGR
SCHEMBL17735806 0.91 PDK2 (0.46) PDK2PGR
SCHEMBL13367418 0.91 PDK2 (0.46) PDK2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170082426-A1 DETECTOR FOR OPTICALLY DETECTING AT LEAST ONE OBJECT BASF SE (DE) 2017-03-23 US disclosed
US-9595678-B2 Dye solar cell with improved stability BASF SE (DE) 2017-03-14 US disclosed
US-9087991-B2 Photovoltaic element BASF SE (DE) 2015-07-21 US disclosed
US-20150124268-A1 DETECTOR FOR OPTICALLY DETECTING AT LEAST ONE OBJECT BASF SE (DE) 2015-05-07 US disclosed
US-9001029-B2 Detector for optically detecting at least one object BASF SE (DE) 2015-04-07 US disclosed
US-20140130870-A1 USE OF TRIARYLAMINE DERIVATIVES AS HOLE-CONDUCTING MATERIALS IN ORGANIC SOLAR CELLS AND ORGANIC SOLAR CELLS CONTAINING SAID TRIARYLAMINE DERIVATIVES BASF SE (DE) 2014-05-15 US disclosed
US-20120279566-A1 PHOTOVOLTAIC ELEMENT WITH INCREASED LONG-TERM STABILITY BASF SE (DE) 2012-11-08 US disclosed
US-20120206336-A1 DETECTOR FOR OPTICALLY DETECTING AT LEAST ONE OBJECT BASF SE (DE) 2012-08-16 US disclosed
US-20120192945-A1 PHOTOVOLTAIC ELEMENT BASF SE (DE) 2012-08-02 US disclosed
US-20120017995-A1 DYE SOLAR CELL WITH IMPROVED STABILITY BASF SE (DE) 2012-01-26 US disclosed
US-20110297235-A1 USE OF TRIARYLAMINE DERIVATIVES AS HOLE-CONDUCTING MATERIALS IN ORGANIC SOLAR CELLS AND ORGANIC SOLAR CELLS CONTAINING SAID TRIARYLAMINE DERIVATIVES BASF SE (DE) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110297235-A1 USE OF TRIARYLAMINE DERIVATIVES AS HOLE-CONDUCTING MATERIALS IN ORGANIC SOLAR CELLS AND ORGANIC SOLAR CELLS CONTAINING SAID TRIARYLAMINE DERIVATIVES NR2E3, NR0B2, AHR PDK2 3106/4885ABL1 2358/4885ABCB1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.